Abstract:Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by excessive circulating toxic lipids, hepatic steatosis, and liver inflammation. Monocyte adhesion to liver sinusoidal endothelial cells (LSECs) and transendothelial migration (TEM) are crucial in the inflammatory process. Under lipotoxic stress, LSECs develop a proinflammatory phenotype known as endotheliopathy. However, mediators of endotheliopathy remain unclear. Methods: Primary mouse LSECs isolated from C57BL/6J mice fed chow or MASH-inducing diets rich in fat, fructose, and cholesterol (FFC) were subjected to multi-omics profiling. Mice with established MASH resulting from a choline-deficient high-fat diet (CDHFD) or FFC diet were also treated with two structurally distinct GSK3 inhibitors (LY2090314 and elraglusib [9-ING-41]). Results: Integrated pathway analysis of the mouse LSEC proteome and transcriptome indicated that leukocyte TEM and focal adhesion were the major pathways altered in MASH. Kinome profiling of the LSEC phosphoproteome identified glycogen synthase kinase (GSK)-3β as the major kinase hub in MASH. GSK3β-activating phosphorylation was increased in primary human LSECs treated with the toxic lipid palmitate and in human MASH. Palmitate upregulated the expression of C-X-C motif chemokine ligand 2, intracellular adhesion molecule 1, and phosphorylated focal adhesion kinase, via a GSK3-dependent mechanism. Congruently, the adhesive and transendothelial migratory capacities of primary human neutrophils and THP-1 monocytes through the LSEC monolayer under lipotoxic stress were reduced by GSK3 inhibition. Treatment with the GSK3 inhibitors LY2090314 and elraglusib ameliorated liver inflammation, injury, and fibrosis in FFC- and CDHFD-fed mice, respectively. Immunophenotyping using cytometry by mass cytometry by time of flight of intrahepatic leukocytes from CDHFD-fed mice treated with elraglusib showed reduced infiltration of proinflammatory monocyte-derived macrophages and monocyte-derived dendritic cells. Conclusion: GSK3 inhibition attenuates lipotoxicity-induced LSEC endotheliopathy and could serve as a potential therapeutic strategy for treating human MASH. Impact and implications: LSECs under lipotoxic stress in MASH develop a proinflammatory phenotype known as endotheliopathy, with obscure mediators and functional outcomes. The current study identified GSK3 as the major driver of LSEC endotheliopathy, examined its pathogenic role in myeloid cell-associated liver inflammation, and defined the therapeutic efficacy of pharmacological GSK3 inhibitors in murine MASH. This study provides preclinical data for the future investigation of GSK3 pharmacological inhibitors in human MASH. The results of this study are important to hepatologists, vascular biologists, and investigators studying the mechanisms of inflammatory liver disease and MASH, as well as those interested in drug development.

Inhibition Of Glycogen Synthase Kinase 3 Beta Ameliorates D-Galn/Lps-Induced Liver Injury By Reducing Endoplasmic Reticulum Stress-Triggered Apoptosis

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

[Protective effect of glycogen synthase kinase 3β inhibition via peroxisome proliferator-activated receptor alpha activation in mice with acute liver failure].

Inhibition of Glycogen Synthase Kinase 3 Beta Ameliorates Liver Ischemia Reperfusion Injury by Way of an Interleukin-10-mediated Immune Regulatory Mechanism.

Inhibition of GSK-3β Ameliorates Hepatic Ischemia-Reperfusion Injury Through GSK-3β/β-catenin Signaling Pathway in Mice

Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

Inhibition of GSK3β activity alleviates acute liver failure via suppressing multiple programmed cell death

Inhibition Of Glycogen Synthase Kinase 3 Beta Protects Liver Against Ischemia/Reperfusion Injury By Activating 5 ' Adenosine Monophosphate-Activated Protein Kinase-Mediated Autophagy

Inhibition of GSK3 beta protects liver against ischemia/reperfusion injury via activating AMPK-mediated autophagy

Endoplasmic reticulum stress promote hepatocyte apoptosis by mediating glycogen synthase kinase 3β

Inhibition of Glycogen Synthase Kinase 3β Protects Liver Against Ischemia/reperfusion Injury by Activating 5′ Adenosine Monophosphate‐activated Protein Kinase‐mediated Autophagy

Glycogen synthase kinase 3 activity enhances liver inflammation in MASH

Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration

Sphingosine kinase 1 inhibition improves lipopolysaccharide/D-galactosamine-induced acute liver failure by inhibiting mitogen-activated protein kinases pathway.

Hepatocyte Gsk3 Inactivation Via Phosphorylations is Essential for Ischemia Reperfusion Induced Inflammatory Cell Death.

Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1

Inhibition of the Translocation and Extracellular Release of High-Mobility Group Box 1 Alleviates Liver Damage in Fibrotic Mice in Response to D-galactosamine/lipopolysaccharide Challenge

Lysine specific demethylase 1 inhibitor alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury

Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-κB, and the induction of autophagy

Ablation of Endothelial Pfkfb3 Protects Mice from Acute Lung Injury in LPS-induced Endotoxemia.